UA104876C2 - Модуляторы атф-связывающих кассетных транспортеров - Google Patents
Модуляторы атф-связывающих кассетных транспортеровInfo
- Publication number
- UA104876C2 UA104876C2 UAA201106975A UAA201106975A UA104876C2 UA 104876 C2 UA104876 C2 UA 104876C2 UA A201106975 A UAA201106975 A UA A201106975A UA A201106975 A UAA201106975 A UA A201106975A UA 104876 C2 UA104876 C2 UA 104876C2
- Authority
- UA
- Ukraine
- Prior art keywords
- atp
- modulators
- binding cassette
- present
- cassette transporters
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Abstract
Соединения по данному изобретению и фармацевтически приемлемые композиции, которые их содержат, используют как модуляторы АТФ-связывающих кассетных (ABC) транспортеров или их фрагменты, включая регулятор трансмембранной проводимости при муковисцидозе (CFTR). Кроме того, данное изобретение касается способов лечения опосредованных ABC-транспортерами заболеваний, в которых используют соединение по данному изобретению.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11215208P | 2008-11-06 | 2008-11-06 | |
PCT/US2008/012689 WO2010053471A1 (en) | 2008-11-06 | 2008-11-12 | Modulators of atp-binding cassette transporters |
Publications (1)
Publication Number | Publication Date |
---|---|
UA104876C2 true UA104876C2 (ru) | 2014-03-25 |
Family
ID=42153560
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201106975A UA104876C2 (ru) | 2008-11-06 | 2008-11-12 | Модуляторы атф-связывающих кассетных транспортеров |
UAA201106976A UA110192C2 (uk) | 2008-11-06 | 2009-06-11 | Модулятори атф-зв'язувальних касетних переносників |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201106976A UA110192C2 (uk) | 2008-11-06 | 2009-06-11 | Модулятори атф-зв'язувальних касетних переносників |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP2362874A2 (ru) |
JP (2) | JP2012508246A (ru) |
KR (1) | KR20110089170A (ru) |
CN (2) | CN105693701B (ru) |
AU (1) | AU2009313409A1 (ru) |
BR (1) | BRPI0921234B8 (ru) |
CA (2) | CA2742980A1 (ru) |
CL (1) | CL2011001004A1 (ru) |
HK (1) | HK1226076A1 (ru) |
IL (2) | IL212727A (ru) |
MX (1) | MX2011004834A (ru) |
NZ (2) | NZ592693A (ru) |
RU (2) | RU2011122646A (ru) |
SG (1) | SG10201501168RA (ru) |
UA (2) | UA104876C2 (ru) |
WO (1) | WO2010054138A2 (ru) |
ZA (1) | ZA201103856B (ru) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
ME02156B (me) | 2004-06-24 | 2015-10-20 | Vertex Pharma | Modulatori atp-vezujućih kasetnih transportera |
ES2431388T3 (es) | 2005-11-08 | 2013-11-26 | Vertex Pharmaceuticals Incorporated | Compuesto heterocíclico útil como un modulador de transportadores de casete de unión a ATP |
PT1993360T (pt) | 2005-12-28 | 2017-05-25 | Vertex Pharma | Formas sólidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-di-hidro-4-oxoquinolina-3-carboxamida |
CN101460489A (zh) | 2006-04-07 | 2009-06-17 | 弗特克斯药品有限公司 | Atp-结合盒转运蛋白调节剂 |
US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
AU2008251504B2 (en) | 2007-05-09 | 2013-07-18 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
RS56083B1 (sr) | 2007-12-07 | 2017-10-31 | Vertex Pharma | Proces za proizvodnju cikloalkilkarboksiamido-piridin benzojevih kiselina |
SG186638A1 (en) | 2007-12-07 | 2013-01-30 | Vertex Pharma | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
WO2009108657A2 (en) | 2008-02-28 | 2009-09-03 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as cftr modulators |
ME02105B (me) * | 2008-11-06 | 2015-10-20 | Vertex Pharma | Modulatori atp-vezujucih kasetnih transportera |
UA104876C2 (ru) * | 2008-11-06 | 2014-03-25 | Вертекс Фармасьютікалз Інкорпорейтед | Модуляторы атф-связывающих кассетных транспортеров |
CA3071058C (en) | 2009-03-20 | 2023-01-24 | Vertex Pharmaceuticals Incorporated | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
DK2826776T3 (da) * | 2010-03-25 | 2020-12-14 | Vertex Pharma | Fast dispersion af amorf form af (r)-1(2,2-difluorbenzo(d)(1,3)dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluor-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl)-cyclopropancarboxamid |
NZ602838A (en) | 2010-04-07 | 2015-06-26 | Vertex Pharma | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof |
WO2011133953A1 (en) * | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
EP3138563A1 (en) * | 2010-04-22 | 2017-03-08 | Vertex Pharmaceuticals Inc. | Pharmaceutical compositions and administrations thereof |
JP2013525371A (ja) | 2010-04-22 | 2013-06-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | シクロアルキルカルボキサミド−インドール化合物の製造方法 |
CA2796646A1 (en) * | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
RU2013112937A (ru) | 2010-08-23 | 2014-09-27 | Вертекс Фармасьютикалз Инкорпорейтед | Фармацевтические композиции (r)-1-(2, 2-дифторбензо[d][1, 3]диоксол-5-ил)-n-(2, 3-дигидроксипропил)-6-фтор-2-(1-гидрокси-2-метилпропан-2-ил)-1н-индол-5-ил)циклопропанкарбоксамида и их применение |
AR085509A1 (es) | 2011-03-09 | 2013-10-09 | Bayer Cropscience Ag | Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas |
AU2013226076B2 (en) | 2012-02-27 | 2017-11-16 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administration thereof |
AU2013290444B2 (en) | 2012-07-16 | 2018-04-26 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof |
TWI692469B (zh) | 2012-11-09 | 2020-05-01 | 南韓商Lg化學股份有限公司 | Gpr40受體促效劑,製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物 |
ITMI20122065A1 (it) | 2012-12-03 | 2014-06-04 | Univ Padova | Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato |
EP2970468B1 (en) | 2013-03-13 | 2021-07-07 | Novartis AG | Notch2 binding molecules for treating respiratory diseases |
KR102280372B1 (ko) | 2013-11-12 | 2021-07-22 | 버텍스 파마슈티칼스 인코포레이티드 | Cftr 매개된 질환 치료용 약제학적 조성물의 제조 방법 |
EP2878339A1 (en) | 2013-12-02 | 2015-06-03 | Siena Biotech S.p.A. | SIP3 antagonists |
AR099336A1 (es) | 2014-02-17 | 2016-07-13 | Bayer Cropscience Ag | Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas |
EP4223294A1 (en) | 2014-04-15 | 2023-08-09 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
EP2932966A1 (en) | 2014-04-16 | 2015-10-21 | Novartis AG | Gamma secretase inhibitors for treating respiratory diseases |
LT3203840T (lt) | 2014-10-06 | 2020-10-26 | Vertex Pharmaceuticals Incorporated | Cistinės fibrozės transmembraninio laidumo reguliatoriaus moduliatoriai |
EP3204358B1 (en) | 2014-10-07 | 2018-09-19 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
AU2015350049B2 (en) | 2014-11-18 | 2021-08-19 | Vertex Pharmaceuticals Incorporated | Process of conducting high throughput testing high performance liquid chromatography |
WO2016109362A1 (en) | 2014-12-31 | 2016-07-07 | Auspex Pharmaceuticals, Inc. | Cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator |
GB201504878D0 (en) | 2015-03-23 | 2015-05-06 | Algipharma As | Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion |
AU2016243171B2 (en) | 2015-03-31 | 2020-10-08 | Concert Pharmaceuticals, Inc. | Deuterated VX-661 |
GB201517639D0 (en) | 2015-10-06 | 2015-11-18 | Algipharma As | Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract |
US10047077B2 (en) | 2016-04-13 | 2018-08-14 | Skyline Antiinfectives, Inc. | Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams |
GEP20217329B (en) | 2016-09-30 | 2021-12-10 | Vertex Pharma | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
EP3812379A1 (en) | 2016-12-09 | 2021-04-28 | Vertex Pharmaceuticals Incorporated | Crystalline form of a n-(pyrazol-4-yl)sulfonyl-6-(pyrazol-1-yl)-2-(pyrrolidin-1-yl)pyridine-3-carboxamide for treating cystic fibrosis |
US11253509B2 (en) | 2017-06-08 | 2022-02-22 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
MA49631A (fr) | 2017-07-17 | 2020-05-27 | Vertex Pharma | Méthodes de traitement de la fibrose kystique |
US11434201B2 (en) | 2017-08-02 | 2022-09-06 | Vertex Pharmaceuticals Incorporated | Processes for preparing pyrrolidine compounds |
US10654829B2 (en) | 2017-10-19 | 2020-05-19 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
AU2018380426B2 (en) | 2017-12-08 | 2023-05-18 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
US11066417B2 (en) | 2018-02-15 | 2021-07-20 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators |
WO2019200246A1 (en) | 2018-04-13 | 2019-10-17 | Alexander Russell Abela | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
CN109651160B (zh) * | 2019-01-25 | 2021-08-13 | 上海应用技术大学 | 一种催化苯乙炔氢胺化反应制备烯胺类化合物的方法 |
CN111763198B (zh) * | 2019-04-01 | 2021-09-07 | 新发药业有限公司 | 一种5-取代环丙基甲酰氨基吲哚衍生物的制备方法 |
US11873300B2 (en) | 2019-08-14 | 2024-01-16 | Vertex Pharmaceuticals Incorporated | Crystalline forms of CFTR modulators |
TW202120517A (zh) | 2019-08-14 | 2021-06-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
TW202115092A (zh) | 2019-08-14 | 2021-04-16 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
CN112624956A (zh) * | 2019-10-08 | 2021-04-09 | 兰州大学 | 3-吲哚磺酸衍生物新型制备方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
EP1554271A1 (en) * | 2002-10-15 | 2005-07-20 | Rigel Pharmaceuticals, Inc. | Substituted indoles and their use as hcv inhibitors |
RU2006111093A (ru) * | 2003-09-06 | 2007-10-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Модуляторы атр-связывающих кассетных транспортеров |
ME02156B (me) * | 2004-06-24 | 2015-10-20 | Vertex Pharma | Modulatori atp-vezujućih kasetnih transportera |
CN101460489A (zh) * | 2006-04-07 | 2009-06-17 | 弗特克斯药品有限公司 | Atp-结合盒转运蛋白调节剂 |
UA104876C2 (ru) * | 2008-11-06 | 2014-03-25 | Вертекс Фармасьютікалз Інкорпорейтед | Модуляторы атф-связывающих кассетных транспортеров |
ME02105B (me) * | 2008-11-06 | 2015-10-20 | Vertex Pharma | Modulatori atp-vezujucih kasetnih transportera |
CN102665715A (zh) * | 2009-10-22 | 2012-09-12 | 沃泰克斯药物股份有限公司 | 治疗囊性纤维化和其他慢性疾病的组合物 |
-
2008
- 2008-11-12 UA UAA201106975A patent/UA104876C2/ru unknown
-
2009
- 2009-06-11 UA UAA201106976A patent/UA110192C2/uk unknown
- 2009-11-06 WO PCT/US2009/063475 patent/WO2010054138A2/en active Application Filing
- 2009-11-06 CN CN201610012624.4A patent/CN105693701B/zh active Active
- 2009-11-06 MX MX2011004834A patent/MX2011004834A/es active IP Right Grant
- 2009-11-06 EP EP09795592A patent/EP2362874A2/en not_active Withdrawn
- 2009-11-06 NZ NZ592693A patent/NZ592693A/xx not_active IP Right Cessation
- 2009-11-06 CA CA2742980A patent/CA2742980A1/en not_active Abandoned
- 2009-11-06 JP JP2011535676A patent/JP2012508246A/ja not_active Withdrawn
- 2009-11-06 AU AU2009313409A patent/AU2009313409A1/en not_active Abandoned
- 2009-11-06 CN CN2009801539702A patent/CN102272128A/zh active Pending
- 2009-11-06 SG SG10201501168RA patent/SG10201501168RA/en unknown
- 2009-11-06 BR BRPI0921234A patent/BRPI0921234B8/pt active IP Right Grant
- 2009-11-06 NZ NZ610972A patent/NZ610972A/en not_active IP Right Cessation
- 2009-11-06 RU RU2011122646/04A patent/RU2011122646A/ru not_active Application Discontinuation
- 2009-11-06 KR KR1020117012767A patent/KR20110089170A/ko not_active Application Discontinuation
- 2009-11-06 CA CA2948104A patent/CA2948104C/en active Active
-
2011
- 2011-05-05 CL CL2011001004A patent/CL2011001004A1/es unknown
- 2011-05-05 IL IL212727A patent/IL212727A/en active IP Right Grant
- 2011-05-25 ZA ZA2011/03856A patent/ZA201103856B/en unknown
-
2012
- 2012-06-01 HK HK16114548A patent/HK1226076A1/zh unknown
-
2014
- 2014-08-07 IL IL233996A patent/IL233996A/en active IP Right Grant
- 2014-09-30 RU RU2014139599A patent/RU2014139599A/ru not_active Application Discontinuation
- 2014-11-25 JP JP2014237756A patent/JP2015061860A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
IL212727A0 (en) | 2011-07-31 |
JP2015061860A (ja) | 2015-04-02 |
CA2948104A1 (en) | 2010-05-14 |
IL233996A0 (en) | 2014-09-30 |
UA110192C2 (uk) | 2015-12-10 |
CN105693701A (zh) | 2016-06-22 |
BRPI0921234A2 (pt) | 2016-02-23 |
CL2011001004A1 (es) | 2012-03-16 |
HK1226076A1 (zh) | 2017-09-22 |
IL233996A (en) | 2015-09-24 |
CA2742980A1 (en) | 2010-05-14 |
CA2948104C (en) | 2017-09-12 |
RU2014139599A (ru) | 2016-04-20 |
WO2010054138A3 (en) | 2010-11-11 |
RU2011122646A (ru) | 2012-12-20 |
WO2010054138A2 (en) | 2010-05-14 |
JP2012508246A (ja) | 2012-04-05 |
BRPI0921234B1 (pt) | 2021-06-22 |
NZ610972A (en) | 2014-11-28 |
ZA201103856B (en) | 2012-02-29 |
EP2362874A2 (en) | 2011-09-07 |
MX2011004834A (es) | 2011-07-28 |
CN102272128A (zh) | 2011-12-07 |
IL212727A (en) | 2014-08-31 |
SG10201501168RA (en) | 2015-04-29 |
BRPI0921234B8 (pt) | 2022-07-19 |
NZ592693A (en) | 2013-05-31 |
AU2009313409A1 (en) | 2010-05-14 |
KR20110089170A (ko) | 2011-08-04 |
CN105693701B (zh) | 2021-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA104876C2 (ru) | Модуляторы атф-связывающих кассетных транспортеров | |
MX357497B (es) | Moduladores de transportadores de casete de union a atp. | |
MX2014005462A (es) | Moduladores de trasportadores de casete enlazante de atp. | |
HK1138586A1 (en) | Modulators of cftr cftr | |
IN2014KN02423A (ru) | ||
AU2010327993A8 (en) | 4-oxo-1H-quinoline-3-carboxamides as modulators of ATP-Binding cassette transporters | |
HK1140475A1 (en) | Azaindole derivatives as cftr modulators | |
NZ583878A (en) | Modulators of ABC transporter and cystic fibrosis transmembrane conductance regulator (CFTR) | |
WO2009038913A3 (en) | Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis | |
WO2009108657A3 (en) | Heteroaryl derivatives as cftr modulators | |
HK1148006A1 (en) | Isoquinoline modulators of atp-binding cassette transporters atp | |
MX341797B (es) | Moduladores de transportadores con casete de union con atp. | |
WO2006099256A3 (en) | Modulators of atp-binding cassette transporters | |
WO2007044560A3 (en) | Modulators of atp-binding cassette transporters | |
NO20082674L (no) | Heterocykliske modulatorer for ATP-bindende kassett-transportere | |
ATE533749T1 (de) | Modulatoren von atp-bindenden kassettentransportern | |
IL189178A0 (en) | Thiazolyl derivatives and pharmaceutical compositions containing the same | |
NZ586271A (en) | Fused pyrimidinone derivatives as modulators of cystic fibrosis transmembrane conductance regulator | |
CY1116953T1 (el) | Παραγωγα πυριδυλιου ως διαμορφωτες cftr | |
EA201170601A1 (ru) | Модуляторы регулятора трансмембранной проводимости при муковисцидозе | |
WO2008147797A3 (en) | Ion channel modulators and methods of use | |
EP2502911A3 (en) | Modulators of ATP-binding cassette transporters |